Without Dosing, Doctors Are Clueless About Medical Weed

Does anyone else get the sense that doctors don’t get the idea behind medical marijuana? It’s either they are too nervous to get registered to offer medical marijuana to their patients, or it’s that they don’t think it has any medical benefits.

Maybe doctors just do not do anything unless they are given detailed instructions that tell them every step they must take. That is understandable considering their liability. Maybe, that is why some people are thinking that without dosing tools or or some map-key to tell doctors what dosage to give their patients, the medical marijuana industry will just never become mainstream. Is dosing technology the key to medical marijuana becoming the next mainstream painkiller?

Making it easier to calibrate the correct dose of medical marijuana may prompt more physicians to prescribe it as an alternative to painkillers such as opioids, according to one Canadian company.

Toronto-based Resolve Digital Health has developed a smart inhaler into which patients insert a pre-measured, single-use cannabis pod filled with dried bud or oil. They then use a mobile application to measure the effectiveness of each treatment, monitor their symptoms and track their consumption, so that dosage levels and marijuana strains can be adjusted as required, Chief Executive Officer Rob Adelson said.

“More and more doctors are getting involved and trying it,” Adelson said by phone. “The medical market is huge.”

Demand for medical cannabis is growing in various countries including in Canada, which plans legalization next year, and where the market could be worth C$1.8 billion ($1.4 billion) by 2021, according to Canaccord Genuity Group Inc. Resolve has struck an agreement with Canadian grower Aphria Inc. and Liberty Health Sciences Inc. to introduce smart weed products to as many as 15,000 patients in Canada and the U.S. in 2018, Adelson said.


Read more…

Show More

Richard Lowe

Richard Lowe is a 14-year veteran of the financial sector with licenses as a commodity broker (Series 3) and investment advisor representative (IAR Series 65). Along with a focus on raising capital for the firms he was employed with, he also wrote and edited much of the content published by them. He holds a BA in Journalism from the University of Massachusetts. He has been a longtime advocate for marijuana legalization due to the social injustices associated with marijuana prohibition and the strong potential for the medicinal benefits of cannabis.

Related Articles

Leave a Reply

Back to top button